Communicating in the Aftermath of ‘Repeal and Replace’
Today’s effective communicators must be comfortable with change, learn how to anticipate it, and adapt messaging to key audiences.
Trump
Five things for pharma marketers to know: Thursday, January 11, 2018
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
From working for one administration to fending off another: Planned Parenthood’s Kevin Griffis
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
Gottlieb Eyes Prices, Not Lives
It turns out the real goal is going after Washington’s favorite whipping boy — high drug prices.
Tax Bill Is Good News for Life Sciences and Marketing
Although it’s a long way from the president’s desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
How will the pharma industry fare in 2018 under Trump?
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Who’s Getting Rich in Healthcare?
Do you recall what President Trump tweeted right after Merck’s Kenneth Frazier resigned from his American Manufacturing Council?
Snubbing Intolerance: Frazier’s Path Was Disengagement
Merck CEO Kenneth Frazier’s exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Frazier’s call earns him praise, rare for a pharma CEO
It’s not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
